Shares of Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.47 and traded as high as $2.25. Galectin Therapeutics shares last traded at $2.25, with a volume of 259,127 shares changing hands.
Wall Street Analyst Weigh In
Several equities analysts recently issued reports on the company. Wall Street Zen upgraded Galectin Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, June 21st. HC Wainwright assumed coverage on Galectin Therapeutics in a research report on Tuesday, June 17th. They issued a "buy" rating and a $6.00 price target on the stock.
Check Out Our Latest Report on Galectin Therapeutics
Galectin Therapeutics Stock Performance
The company has a 50-day simple moving average of $1.72 and a 200-day simple moving average of $1.48. The company has a market cap of $158.23 million, a price-to-earnings ratio of -3.47 and a beta of 0.70.
Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.05. As a group, equities research analysts forecast that Galectin Therapeutics Inc. will post -0.73 EPS for the current year.
Institutional Investors Weigh In On Galectin Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the company. PNC Financial Services Group Inc. acquired a new stake in shares of Galectin Therapeutics in the 4th quarter worth approximately $26,000. Inspire Advisors LLC lifted its stake in Galectin Therapeutics by 86.3% in the 4th quarter. Inspire Advisors LLC now owns 21,095 shares of the company's stock valued at $27,000 after buying an additional 9,772 shares in the last quarter. HighTower Advisors LLC purchased a new position in shares of Galectin Therapeutics during the 4th quarter worth $29,000. Nuveen LLC purchased a new position in shares of Galectin Therapeutics in the 1st quarter worth $34,000. Finally, Two Sigma Securities LLC purchased a new position in shares of Galectin Therapeutics in the 4th quarter worth $37,000. Institutional investors and hedge funds own 11.68% of the company's stock.
About Galectin Therapeutics
(
Get Free Report)
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.
Featured Stories
Before you consider Galectin Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Galectin Therapeutics wasn't on the list.
While Galectin Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
